EP3307067A4 - Aminopyrazine compounds with a2a antagonist properties - Google Patents

Aminopyrazine compounds with a2a antagonist properties Download PDF

Info

Publication number: EP3307067A4
Authority: EP; European Patent Office
Prior art keywords: antagonist properties; aminopyrazine compounds; aminopyrazine; compounds; antagonist
Prior art date: 2015-06-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP16808075.2A

Other languages

German (de)

French (fr)

Other versions

EP3307067A1 (en

EP3307067B1 (en

Inventor

Junying Zheng

Walter Won

Michael Berlin

Pauline Ting

Guoqing Li

Dong Xiao

Hongwu Wang

Robert Aslanian

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Merck Sharp and Dohme Ltd

Merck Sharp and Dohme LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-11

Filing date

2016-06-06

Publication date

2018-12-05

2016-06-06 Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd

2018-04-18 Publication of EP3307067A1 publication Critical patent/EP3307067A1/en

2018-12-05 Publication of EP3307067A4 publication Critical patent/EP3307067A4/en

2022-11-02 Application granted granted Critical

2022-11-02 Publication of EP3307067B1 publication Critical patent/EP3307067B1/en

Status Active legal-status Critical Current

2036-06-06 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Plant Pathology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Neurology (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Environmental Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Dispersion Chemistry (AREA)
Toxicology (AREA)

EP16808075.2A 2015-06-11 2016-06-06 Aminopyrazine compounds with a2a antagonist properties Active EP3307067B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562174295P	2015-06-11	2015-06-11
PCT/US2016/035960 WO2016200717A1 (en)	2015-06-11	2016-06-06	Aminopyrazine compounds with a2a antagonist properties

Publications (3)

Publication Number	Publication Date
EP3307067A1 EP3307067A1 (en)	2018-04-18
EP3307067A4 true EP3307067A4 (en)	2018-12-05
EP3307067B1 EP3307067B1 (en)	2022-11-02

Family

ID=57503919

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16808075.2A Active EP3307067B1 (en)	2015-06-11	2016-06-06	Aminopyrazine compounds with a2a antagonist properties

Country Status (3)

Country	Link
US (1)	US10688082B2 (en)
EP (1)	EP3307067B1 (en)
WO (1)	WO2016200717A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12414952B2 (en)	2018-11-20	2025-09-16	Merck Sharp & Dohme Llc	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019383948A1 (en)	2018-11-20	2021-05-20	Merck Sharp & Dohme Llc	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112700A1 (en)	2018-11-30	2020-06-04	Merck Sharp & Dohme Corp.	9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en)	2018-11-30	2021-05-27	Merck Sharp & Dohme Llc	7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
MX2021008094A (en)	2019-01-11	2021-09-21	Omeros Corp	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER.
WO2022020550A1 (en) *	2020-07-24	2022-01-27	Merck Sharp & Dohme Corp.	Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
JP2025512384A (en)	2022-04-13	2025-04-17	ギリアードサイエンシーズ，インコーポレイテッド	Combination Therapies for Treating TROP-2-Expressing Cancers
US12516018B2 (en) *	2023-03-30	2026-01-06	Brandeis University	Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
US12180208B1 (en) *	2024-01-19	2024-12-31	King Faisal University	Pyrazolo[1,5-c]pyrido[3,4-e]pyrimidines as CK2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3531482A (en) *	1966-10-13	1970-09-29	Sandoz Ag	Pyrazolo(1,5-c)quinazolines
IT1264901B1 (en)	1993-06-29	1996-10-17	Schering Plough S P A	HETEROCYCLIC ANALOGUES OF 1,2,4-TRIAZOLE(15-C)PYRIMIDINES WITH ANTAGONIST ACTIVITY FOR THE ADENOSINE A2 RECEPTOR
WO1995003806A1 (en)	1993-07-27	1995-02-09	Kyowa Hakko Kogyo Co., Ltd.	Remedy for parkinson's disease
IT1277392B1 (en)	1995-07-28	1997-11-10	Schering Plough S P A	HEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C] PYRIMIDINE WITH ANTAGONIST ACTIVITY FOR THE A2A RECEPTOR OF ADENOSINE
IT1291372B1 (en)	1997-05-21	1999-01-07	Schering Plough S P A	USE OF HETEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C) PYRIMIDINS FOR THE PREPARATION OF MEDICATIONS USEFUL FOR THE TREATMENT OF DISEASES
DE60110219T2 (en)	2000-05-26	2006-03-09	Schering Corp.	ADENOSINE A2A RECEPTOR ANTAGONISTS
AR073574A1 (en) *	2008-09-10	2010-11-17	Alcon Res Ltd	HETEROCICLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF A DISEASE
US20150174130A1 (en) *	2012-07-26	2015-06-25	Vanderbilt University	Compositions and methods for treating microbial infections
WO2014101120A1 (en) *	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2015027431A1 (en) *	2013-08-29	2015-03-05	Merck Sharp & Dohme Corp.	2,2-difluorodioxolo a2a receptor antagonists

2016
- 2016-06-06 WO PCT/US2016/035960 patent/WO2016200717A1/en not_active Ceased
- 2016-06-06 US US15/815,212 patent/US10688082B2/en active Active
- 2016-06-06 EP EP16808075.2A patent/EP3307067B1/en active Active

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CATARZI D ET AL: "Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: Synthesis, structure-affinity relationships and molecular modeling studies", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, no. 1, 1 January 2013 (2013-01-01), pages 283 - 294, XP028961394, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2012.10.031 *
See also references of WO2016200717A1 *
YANG X ET AL: "Easy and efficient one-pot synthesis of pyrazolo[1,5-c]quinazolines under mild copper-catalyzed conditions", RSC ADVANCES, vol. 2, no. 29, 19 September 2012 (2012-09-19), pages 11061, XP055516027, ISSN: 2046-2069, DOI: 10.1039/c2ra21929h *

Also Published As

Publication number	Publication date
EP3307067A1 (en)	2018-04-18
US20180193314A1 (en)	2018-07-12
EP3307067B1 (en)	2022-11-02
WO2016200717A1 (en)	2016-12-15
US10688082B2 (en)	2020-06-23

Legal Events

Date	Code	Title	Description
2016-12-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-03-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-03-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-04-18	17P	Request for examination filed	Effective date: 20180111
2018-04-18	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-04-18	AX	Request for extension of the european patent	Extension state: BA ME
2018-09-19	DAV	Request for validation of the european patent (deleted)
2018-09-19	DAX	Request for extension of the european patent (deleted)
2018-12-05	A4	Supplementary search report drawn up and despatched	Effective date: 20181026
2018-12-05	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/519 20060101ALI20181022BHEP Ipc: A61K 31/4162 20060101ALI20181022BHEP Ipc: C07D 487/04 20060101ALI20181022BHEP Ipc: A61P 25/00 20060101AFI20181022BHEP Ipc: A61K 31/497 20060101ALI20181022BHEP Ipc: C07D 487/10 20060101ALI20181022BHEP
2020-05-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-06-10	17Q	First examination report despatched	Effective date: 20200511
2022-04-07	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602016076091 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0043420000 Ipc: A01N0043800000
2022-05-12	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2022-05-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2022-05-18	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/00 20060101ALI20220407BHEP Ipc: C07D 487/10 20060101ALI20220407BHEP Ipc: C07D 487/04 20060101ALI20220407BHEP Ipc: A61K 31/519 20060101ALI20220407BHEP Ipc: A61K 31/497 20060101ALI20220407BHEP Ipc: A61K 31/4162 20060101ALI20220407BHEP Ipc: A01N 43/80 20060101AFI20220407BHEP
2022-06-08	INTG	Intention to grant announced	Effective date: 20220513
2022-09-23	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2022-09-30	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2022-09-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2022-10-19	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MERCK SHARP & DOHME LLC
2022-11-02	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-11-02	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2022-11-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1528082 Country of ref document: AT Kind code of ref document: T Effective date: 20221115
2022-11-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602016076091 Country of ref document: DE
2022-12-07	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2023-02-27	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2023-03-08	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20221102
2023-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1528082 Country of ref document: AT Kind code of ref document: T Effective date: 20221102
2023-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230302 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230202 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2023-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230302 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230203
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2023-07-05	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230526
2023-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2023-08-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602016076091 Country of ref document: DE
2023-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2023-09-08	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2023-09-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2023-10-11	26N	No opposition filed	Effective date: 20230803
2023-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2024-01-19	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2024-01-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2024-02-26	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20230630
2024-03-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230606
2024-03-27	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2024-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230606
2024-04-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230606
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230606 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230630
2024-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230630
2024-11-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2024-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102
2025-07-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20250509 Year of fee payment: 10
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250508 Year of fee payment: 10
2025-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250512 Year of fee payment: 10
2025-07-25	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160606
2025-08-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160606
2025-12-12	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221102

Publication	Publication Date	Title
EP3220910A4 (en)	2018-04-25	Aminopyrazine compounds with a2a antagonist properties
IL254870A0 (en)	2017-12-31	Substituted quinoxaline derivatives
EP3284980A4 (en)	2018-12-05	Sliding part
EP3299685A4 (en)	2018-12-05	Sliding component
EP3284981A4 (en)	2019-03-20	Sliding parts
EP3299686A4 (en)	2018-12-26	Sliding component
EP3258145A4 (en)	2018-10-24	Sliding component
EP3252354A4 (en)	2018-10-17	Sliding part
EP3307067A4 (en)	2018-12-05	Aminopyrazine compounds with a2a antagonist properties
EP3253390A4 (en)	2018-06-06	Aminoquinazoline compounds as a2a antagonist
EP3331532A4 (en)	2018-12-05	Substituted aminoquinazoline compounds as a2a antagonist
EP3270016A4 (en)	2018-11-07	Sliding component
EP3272750A4 (en)	2018-08-08	Morphinan derivative
EP3272627A4 (en)	2018-11-07	Multi-purpose vehicle
EP3216865A4 (en)	2018-05-23	Amadoriase having improved anionic-surfactant resistance
EP3276117A4 (en)	2018-11-21	Double-canvas door
HK1260498A1 (en)	2019-12-20	Materials with improved properties
EM31551260010S (en)	2016-10-14	Doors
EM31551260005S (en)	2016-10-14	Doors
EM31551260004S (en)	2016-10-14	Doors
EM31551260001S (en)	2016-10-14	Doors
EM31551260006S (en)	2016-10-14	Doors
EM31551260007S (en)	2016-10-14	Doors
EM31551260003S (en)	2016-10-14	Doors
EM31551260002S (en)	2016-10-14	Doors